GX Genomic Biotech UCITS ETF (GNOM)

Overview

The fund is primarily focused on investing in a range of securities that are part of the underlying index managed by Solactive AG. This index is specifically tailored to capture the growth and advancements in the field of genomics and biotechnology. By allocating at least 80% of its total assets to these securities, the fund seeks to offer investors exposure to companies that stand to benefit from innovations and developments in genomic science and its applications. This approach emphasizes the fund’s commitment to concentrating on a specialized segment of the market, aiming to leverage the potential high-growth area of Genomics & Biotechnology Companies. Despite its specialized focus, the fund is classified as non-diversified, meaning it may invest more heavily in a smaller number of positions and thus can carry more risk.

Products and Services

• Securities of the Underlying Index

The primary product of the fund is the investment in securities that form the underlying index constructed by Solactive AG. These securities are carefully selected to represent companies that are at the forefront of genomic science and biotechnology. This focus area includes, but is not limited to, companies involved in DNA sequencing, development of new treatments and medicines through genetic analysis, and biotechnological applications that offer innovative solutions in healthcare.

• Exposure to Genomics & Biotechnology Companies

By focusing on Genomics & Biotechnology Companies, the fund provides its investors with the opportunity to be part of the advancements in genomic science. This includes companies that are working on cutting-edge research, developing therapies and cures for various diseases, and applying biotechnological innovations to improve health outcomes. The fund’s strategy is designed to tap into the potential for substantial growth in this area, appealing to investors who are interested in the convergence of technology and healthcare.